Biofrontera falls as Q1 revenue misses, CEO resigns
** Drug developer Biofrontera Inc's BFRI.O shares fall
28.6% to $0.40
** Stock set for biggest one-day pct drop in over a year
** Company reports Q1 revenue of $8.73 mln vs est $9.15 mln
- Refinitiv
** Biofrontera says Chief Executive Officer Erica Monaco
will step down
** Hermann Luebbert, BFRI's executive chairman and founder,
will assume role of CEO
** Including session moves, stock down ~51% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales